Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIOCRYST PHARMACEUTICALS INCBCRX · Entity 315 | Chief Business Officer | December 15, 2020 | December 17, 2020 |
| Praxis Precision Medicines, Inc.PRAX · Entity 3538 | Chief Operating Officer | May 14, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIOCRYST PHARMACEUTICALS INC
Report date December 15, 2020 · Filed December 17, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Emp. Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.31 · Expires 2030-12-15 | Direct | 225,000 |
Reported balance
After 2020-12-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-12-15 · Grant · Acquired 225,000 · Balance 225,000 F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.
Praxis Precision Medicines, Inc.
Report date May 14, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 28,664 |
Reported balance
After 2026-05-14 transaction · row 1
1 source rowRow 1 · 2026-05-14 · Grant · Acquired 89 · Balance 28,664 F1: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 14, 2026 Filed May 20, 2026 01:43 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 89 | $167.94 | $14,946.93 |
DisclosureSEC source: 0001781480-26-000008 · wk-form4_1779241385.xml · nonDerivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,664 F1 · kind: These shares were acquired under the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
| January 12, 2026 Filed Jan 14, 2026 01:19 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 885 | $275.74 | $244,029.90 |
DisclosureSEC source: 0001781480-26-000006 · wk-form4_1768353587.xml · nonDerivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,530 F1 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| January 10, 2026 Filed Jan 12, 2026 22:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | Tax withholdingCommon Stock | 1,087 | $288.45 | $313,545.15 |
DisclosureSEC source: 0001689548-26-000013 · wk-form4_1768258226.xml · nonDerivative · entry 2 Sniecinski Megan · CIK 0001781480 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,415 F2 · kind: Shares withheld by the Issuer to satisfy the tax withholding obligations in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantStock Option (Right to Buy) · Derivative | 7,700 | $0.00 Strike: $294.38 | $0.00 |
DisclosureSEC source: 0001689548-26-000013 · wk-form4_1768258226.xml · derivative · entry 3 Sniecinski Megan · CIK 0001781480 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2036-01-08 F3 · derivative.exercise_date: The shares underlying this stock option vest over a four-year period, with 25% vesting on January 8, 2027 and the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the reporting person's continued service through each vesting date. Read SEC document |
| January 08, 2026 Filed Jan 12, 2026 22:50 UTC | Praxis Precision Medicines, Inc. PRAX · Entity 3538 | GrantCommon Stock | 9,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001689548-26-000013 · wk-form4_1768258226.xml · nonDerivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,502 F1 · kind: Ms. Sniecinski was awarded 9,625 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The restricted stock units vest in equal annual installments over a four-year period beginning on the one-year anniversary of the vesting commencement date of January 8, 2026. The restricted stock units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance. Read SEC document |
| December 15, 2020 Filed Dec 17, 2020 21:45 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001127602-20-031803 · form4.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2030-12-15 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 19, 2019 22:49 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 202,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035549 · form4.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,000 Underlying: Common Stock · 202,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| December 17, 2019 Filed Dec 26, 2019 22:13 UTC Amendment | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $3.23 | $0.00 |
DisclosureSEC source: 0001127602-19-035852 · form4a.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2029-12-17 F1 · shares: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant. Read SEC document |
| November 18, 2019 Filed Nov 18, 2019 21:16 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | PurchaseCommon Stock | 45,000 | $1.45 | $65,250.00 |
DisclosureSEC source: 0001127602-19-033033 · form4.xml · nonDerivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 17:25 UTC | BIOCRYST PHARMACEUTICALS INC BCRX · Entity 315 | GrantEmp. Stock Option (Right to Buy) · Derivative | 500,000 | $0.00 Strike: $3.71 | $0.00 |
DisclosureSEC source: 0001127602-19-023901 · form4.xml · derivative · entry 1 Sniecinski Megan · CIK 0001781480 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2029-07-01 F1 · shares: Inducement option grant becomes exercisable at the rate of 30% on the first anniversary of the grant date with the remainder vesting in three equal installments on the second, third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.